Chinese CDMO GenScript takes steps to be player in China's gene and cell therapy market

DNA
Chinese CDMO GenScript Biotech is building facilities that will allow it to compete in the biologic and cell and gene-based treatments manufacturing market in the country. (LionFive/Pixabay)

With Western drugmakers taking new-generation meds to China, GenScript Biotech is looking to be a key player in China’s CDMO market for biologics and cell and gene-based treatments. The Chinese company this week formally premiered a clinical supply manufacturing facility even as it is working on a commercial-scale facility nearby.

GenScript has opened a 9,300-square-meter (100,104-square-foot) clinical supply biologics production and R&D facility in Nanjing that was completed in June. The company said it meets both FDA and EMA standards.  

“At the beginning of 2019, we established a foothold in the biologics sector as an independent business,” Brian Min, CEO of biologics for GenScript Biotech, said in a statement. “GenScript's planned biologics commercial production center will be the first and largest such facility in China covering cell therapy, gene therapy and antibody drug R&D. We will be able to meet the rapidly evolving demands of gene and cell and antibody and protein therapies.”

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

RELATED: China's GenScript starts on plasmid, virus making facility 

GenScript in April began construction on that facility which will be capable of doing plasmid and virus manufacturing. The 150,000-square-meter facility in Zhenjiang is also being designed to meet FDA and EMA standards as well as those of China's National Medical Products Administration. 

The company has said the plasmid service line will be equipped with single-use bioreactors while the virus line will use suspension-based production processes. It said the facility will be able to handle phase 3 clinical supplies and commercial production. It expects to have the facility in production in 2020.

The GenScript facility already has a deal to produce a CAR-T drug being developed by its Legend Biotech unit and Janssen. 

Read more on

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.